GLP1R and diabetes mellitus: Several clinical trials to date have demonstrated a protective effect of GLP1-Ra regarding major cardiovascular events, namely LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results), SUSTAIN-6 (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes 6), Harmony Outcomes with Albiglutide, REWIND (Researching Cardiovascular Events With a Weekly Incretin in Diabetes) with dulaglutide, and the AMPLITUDE-O trial (Effect of Efpeglenatide on Cardiovascular Outcomes) [29,30,31,32,33].